Merck's Q4 2015 earnings call highlights strong operational performance, exceeding EPS guidance.  Management expresses confidence in 2016 growth, driven by new product launches like ZEPATIER and KEYTRUDA, and a focus on prioritized resource allocation.  While currency headwinds remain, the call indicates a positive outlook for the short term with continued investment in key brands.
[1]
